Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy

Maria I. Carlo,Kyrollis Attalla,Yousef Mazaheri,Sounak Gupta,Onur Yildirim,Samuel J. Murray,Devyn T. Coskey,Ritesh Kotecha,Chung-Han Lee,Darren R. Feldman,Paul Russo,Sujata Patil,Robert J. Motzer,Jonathan A. Coleman,Jeremy C. Durack,Ying-Bei Chen,Oguz Akin,A. Ari Hakimi,Martin H. Voss

European Urology（2022）

引用 19|浏览30

暂无评分

摘要

In a study of preoperative nivolumab in patients with localized renal cell carcinoma, the approach appeared to be safe and feasible, with most patients completing therapy without surgical delays. Preliminary data show that radiomics as a predictive biomarker could be explored further.

查看译文

关键词

Immune checkpoint inhibitors,Immunotherapy,Neoadjuvant,Nephrectomy,Renal cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要